Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504028 | 1.00 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1PEPDMEN1 | |
| SCHEMBL2277633 | 1.00 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1PEPDMEN1 | |
| SCHEMBL11597749 | 1.00 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1PEPDMEN1 | |
| SCHEMBL9019456 | 0.95 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL19733794 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL20979921 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL19733793 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL20979912 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL20226843 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL11695757 | 0.93 | PEPD (0.43) | GABRR1PEPDMEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| CN-120530099-A | Pharmaceutically acceptable salts and crystal forms of triazole compounds and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2025-08-22 | — | — | CN | disclosed |
| CN-118359590-A | Triazole compound | 上海拓界生物医药科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117460721-A | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3226690-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226689-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-5447933-A | Antidementia activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-09-05 | — | — | US | disclosed |
| US-5336769-A | Anti-dementia drug | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| US-5290782-A | Bronchodilator agents, diuretics for renal protective agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
| EP-0556778-A2 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
| EP-0421752-A2 | Substituted acrylamido-penicillanic acid derivatives | Beecham Group p.l.c. (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0415456-A2 | Xanthine compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4925956-A | Novel process for manufacturing optically active carbacyclin intermediates | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | disclosed |
| US-4925956-A | Novel process for manufacturing optically active carbacyclin intermediates | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | disclosed |